8-K: Coherus Oncology Reports Q2 2026 Results, LOQTORZI Revenue Up

Coherus Oncology announced second quarter 2026 financial results, reporting $13.6 million in LOQTORZI net revenue, a 15% increase from the previous quarter, alongside updates on its clinical pipeline.

Summary

• Coherus Oncology reported Q2 2026 financial results, with LOQTORZI net revenue reaching $13.6 million, a 15% increase from Q1 2026 and a 37% increase from Q2 2025.
• The company experienced its highest number of new patient starts for LOQTORZI since launch.
• R&D expenses decreased to $21.4 million in Q2 2026 from $26.3 million in Q2 2025, attributed to reduced headcount and lower clinical trial costs.
• SG&A expenses also decreased to $21.0 million in Q2 2026 from $26.0 million in Q2 2025, due to lower headcount and exit from the biosimilar business.
• Net loss from continuing operations for Q2 2026 was $33.3 million, or $(0.22) per share, an improvement from a net loss of $44.9 million, or $(0.39) per share, in Q2 2025.
• Cash, cash equivalents, and marketable securities stood at $105.3 million as of June 30, 2026, down from $172.1 million as of December 31, 2025.
• Clinical data readouts for tagmokitug and casdozokitug are expected in the second half of 2026.
• A Phase 1b study for tagmokitug in combination with pasritamig is expected to initiate in Fall 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive report, with revenue growth and pipeline advancements offset by continued net losses and a decrease in cash reserves.

Positives

• LOQTORZI net revenue increased by 15% sequentially to $13.6 million in Q2 2026 and by 37% year-over-year from Q2 2025.
• Achieved the highest number of new patient starts for LOQTORZI since its launch.
• Continued improvement in therapy duration for LOQTORZI.
• Reduced R&D expenses by $4.9 million year-over-year in Q2 2026.
• Reduced SG&A expenses by $5.0 million year-over-year in Q2 2026.
• Narrowed net loss from continuing operations to $33.3 million in Q2 2026 from $44.9 million in Q2 2025.
• Emerging evidence of clinical activity with tagmokitug in combination with toripalimab in head and neck cancer.
• Enrollment completed for casdozokitug in HCC and tagmokitug in CRC studies, with data readouts expected in 2H 2026.

Negatives

• The company reported a net loss from continuing operations of $33.3 million in Q2 2026.
• Cash, cash equivalents, and marketable securities decreased to $105.3 million as of June 30, 2026, from $172.1 million as of December 31, 2025.
• The company has a history of net losses from continuing operations, with $70.3 million reported for the first half of 2026.
• The company's strategy relies on future fundraising, which may not be available on acceptable terms or at all.

Risks

• Risks and uncertainties inherent in the clinical drug development process.
• Dependence on the ability to raise funds in the future, which may not be available on acceptable terms or at all.
• Risks related to existing and potential collaboration partners.
• Risks of Coherus' competitive position with LOQTORZI and its product candidates.
• Risks associated with the ability to successfully commercialize and maintain and increase revenues for LOQTORZI.
• Risks and uncertainties of the regulatory approval process, including the speed of regulatory review and the timing of regulatory filings.
• Risk of FDA review issues.
• Risks and uncertainties of possible litigation.

Future Outlook

The company anticipates public disclosure of data sets with sufficient maturity for tagmokitug and casdozokitug in the second half of 2026. A Phase 1b clinical study evaluating tagmokitug in combination with pasritamig is expected to initiate in the fall of 2026. The company plans to grow sales of LOQTORZI and advance its pipeline candidates, potentially through strategic partnerships and ex-U.S. licensing deals.

Management Comments

• "During the second quarter we continued to pursue our science-driven clinical development strategy, creating multiple avenues for long-term value creation, and look forward to further maturation of data with both tagmokitug and casdozokitug."
• "We continue to advance our pipeline studies, including completion of enrollment with casdozokitug in HCC, as well as with tagmokitug in HNSCC and CRC, with emerging evidence of clinical activity in combination with toripalimab in HNSCC. While preliminary, the activity observed to date reinforces our confidence in the Treg depletion mechanism."

Industry Context

StockSavvy.ai notes that Coherus Oncology is operating in the highly competitive and capital-intensive oncology drug development sector. The reported revenue growth for LOQTORZI is a positive sign, but the company's continued reliance on pipeline development and potential future fundraising highlights the inherent risks in this industry. The focus on novel mechanisms like Treg depletion and IL-27 antagonism reflects broader industry trends towards targeted immunotherapies.

Comparison to Industry Standards

• No direct comparisons to specific industry benchmarks or competitor financial results were provided in the filing.
• The net loss from continuing operations is a common characteristic for many clinical-stage biotechnology companies, but the magnitude and cash burn rate are key factors for investor evaluation.

Stakeholder Impact

• Shareholders: Continued net losses and decreasing cash reserves may impact investor confidence and stock valuation, though pipeline progress offers potential future upside.
• Employees: Reductions in R&D and SG&A expenses, partly due to headcount reduction, could affect employee morale and workload.
• Creditors: The company's cash position and ongoing losses will be monitored by creditors.
• Partners (e.g., Junshi Biosciences): Continued collaboration and data sharing are crucial for advancing pipeline candidates.

Next Steps

• Public disclosure of data sets for tagmokitug and casdozokitug in 2H 2026.
• Initiate Phase 1b study for tagmokitug in combination with pasritamig in Fall 2026.
• Continue to advance pipeline studies.
• Grow sales of LOQTORZI.
• Execute ex-U.S. licensing deals as clinical data supports.

Key Dates

Recommendation

The company shows positive revenue growth for its key product, LOQTORZI, and progress in its pipeline. However, the continued significant net losses and reduction in cash reserves necessitate a cautious approach. A 'hold' recommendation reflects the balance between current performance and future potential, pending further clinical data and financial stability.

Keywords

oncology, LOQTORZI, toripalimab, tagmokitug, casdozokitug, clinical trials, nasopharyngeal carcinoma, head and neck cancer